What is Cresemba and what is it used for?
Cresemba is an antifungal medicine that works by blocking the production of a key component of the cell membrane of fungi. This weakens the membrane, therefore preventing fungal cell growth.
Cresemba is available as capsules and in an injectable form. In adults (aged 18 and over), it can be used to treat:
- invasive aspergillosis
- mucormycosis in patients for whom amphotericin B is inappropriate.
These fungal infections may occur in patients being treated for blood cancers, transplant recipients and patients in intensive care units. They are challenging to treat and have a high mortality rate.
The medicine can only be obtained with a prescription.
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU). The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See EMA guidance on Cresemba.
Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) since the UK left the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Cresemba, please follow these links:
PP-CRB-GBR-1299 / October 2021